AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plc (NASDAQ: AZN) COVID vaccine generated $894 million in sales in Q2. The group added that it shipped about 319 million doses worldwide during 1H of 2021, which included $572 million in Europe and $455 million in emerging markets.

AstraZeneca Stock Gains As Q2 Earnings Beat Forecasts, Clocks $894M In COVID-19 Vaccine Sales

AstraZeneca is exploring its options for the future of its COVID-19 vaccine business and expects greater clarity on the matter by the end of 2021, a senior executive told Reuters on Thursday.

Exclusive-AstraZeneca exploring options for COVID-19 vaccine business, exec says

AstraZeneca PLC has announced higher full-year guidance to include the newly acquired Alexion, after the transaction was completed last week. The pharma giant expects total revenue to jump 21-22%, with core earnings per share (EPS) from US$5.05 to US$5.40.

AstraZeneca eyes big jump in revenue after Alexion acquisition

Speaking to CNBC, AstraZeneca's CEO said the company did not have a "precise answer" on whether a third dose of its Covid-19 vaccine would be needed.

‘Not clear yet' if booster shots of Covid vaccine are needed, AstraZeneca CEO says

AstraZeneca's COVID-19 vaccine sales more than tripled to $894 million in the second quarter from the previous three months but shaved off 1 U.S. cent from earnings, and the drugmaker updated its 2021 forecasts on Thursday to include sales from its Alexion unit.

AstraZeneca COVID vaccine sales jump to $894 million, updates forecasts

The shares of AstraZeneca plc (NYSE:AZN) are down 0.3%, last seen trading at $57.27 as the vaccine staple gets ready to step into the earnings confessional.

Vaccine Staple Trades Flat Ahead of Earnings

A person's risk of blood clots does not increase after the second Oxford/AstraZeneca plc (NASDAQ: AZN) COVID-19 vaccine shot. The Company is trying to boost confidence in its jab, which has taken a beating after reports of rare but serious blood clotting events after vaccination.

No Increased Risk Of Blood Clots After Second Dose Of AstraZeneca's COVID-19 Shot, Study Shows

Hutchison China MediTech Ltd.

HUTCHMED (China) Limited (NASDAQ: HCM) and AstraZeneca Plc (NASDAQ: AZN) have initiated a Phase 2 study of Orpathys (savolitinib) in patients with advanced or metastatic MET amplified gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (GEJ).  Orpathys is an oral, potent, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase.

Hutchmed Stock Gains On Kick Starting Mid-Stage Gastric Cancer Trial With AstraZeneca's Orpathys

The study confirmed an elevated risk of rare blood clotting after the first dose, though experts stress this is small compared to the risk of Covid-19.

No Increased Risk Of Blood Clotting After Second AstraZeneca Shot, Study Finds

AstraZeneca says blood-clot risk isn't increased by two doses of vaccine

Comcast

Merck

Three of the five largest U.S. traded companies will report June-quarter earnings after markets close Tuesday.

Earnings Previews: AstraZeneca, Comcast, Merck

Regeneron Pharmaceuticals

Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Tuesday after the company announced a deal with AstraZeneca to develop and commercialize obesity treatments that target a specific gene, GPR75. The companies will split development costs and profits if the drug is successful.

Regeneron, AstraZeneca to develop obesity treatment

Pfizer

The study follows another by Oxford University that found taking an AstraZeneca vaccine shot followed by a Pfizer shot created a high immune repsonse.

Mixed Astra-Zeneca-Pfizer Vaccine Boosts Covid Antibody Levels, Korea Study Finds

AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.

What's in the Cards for AstraZeneca (AZN) in Q2 Earnings?

AstraZeneca Plc (NASDAQ: AZN) said that the European Medicines Agency (EMA) has recommended approving a medicine from its recently acquired Alexion for a rare, deadly blood disorder in children and adolescents aged up to 18 years. Ultomiris has been given a positive opinion for paroxysmal nocturnal hemoglobinuria (PNH) by the human medicines committee of the EMA, and it follows the U.S. approval for adolescents in June.

EMA's CHMP Backs AstraZeneca's Drug For Rare Blood Disorder In Children

Alexion Pharma

AstraZeneca PLC (LON:AZN) announced that Alexion's Ultomiris has been recommended for marketing authorisation in the EU for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on interim results from the Phase III clinical trial in children and teens with PNH.

AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids

Aerojet Rocketdyne Holdings

Emergent BioSolutions

Jacobs Solutions Inc

Leidos Hld

Lockheed Martin

Moderna

Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.

These Companies Have Seen Large Returns From 2020 Government Investment

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Budureon BCise (exenatide extended-release), once-weekly injectable suspension for type 2 diabetes (T2D) in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval was supported by the positive results of the BCB114 Phase 3 trial, which showed that on top of standard of care, exenatide extended-release significantly improved glycemic control compared to placebo in pediatrics.

AstraZeneca's Once-Weekly Diabetes Med Wins FDA Nod For Use In Children

Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine was 82% effective against hospitalization or death caused by the Beta/Gamma COVID-19 variants. Dubbed Vaxzevria, the vaccine also showed a high level of effectiveness against the Delta (B.617.2, 'Indian') and Alpha (B.1.1.7, 'Kent') variants with 87% and 90% reduction in hospitalizations or deaths, respectively.

Real-World Data In Canada Shows AstraZeneca's COVID-19 Jab Is Over 80% Effective Against Variants

One dose of either vaccine is less than 40% effective, researchers said.

Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses

Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Aridis Pharmaceuticals

LOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab.

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca

National Medical Products Administration of China has approved AstraZeneca plc's (NASDAQ: AZN) Imfinzi (durvalumab) to treat an aggressive type of lung cancer in adults. The approval comes for the 1st-line treatment of adult patients with extensive-stage small-cell lung cancer, combined with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).

China Approves AstraZeneca's Imfinzi For Extensive-Stage Small Cell Lung Cancer

AstraZeneca PLC (LON:AZN) announced that Imfinzi has been approved in China for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). It will be used in combination with standard of care platinum chemotherapy.

News for AstraZeneca Stock (AZN)